{"id":5397,"date":"2021-05-22T11:49:30","date_gmt":"2021-05-22T11:49:30","guid":{"rendered":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=5397"},"modified":"2021-05-22T11:50:24","modified_gmt":"2021-05-22T11:50:24","slug":"budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/","title":{"rendered":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions"},"content":{"rendered":"\n





AMB 2021, 55<\/strong> , 37   <\/p>\n\n\n\n


Summary: A very small, controlled, randomized and open-label phase II study in 146 participants has shown that inhalation treatment with budesonide powder for a few days in patients with mild COVID-19 symptoms (cough, fever and \/ or anosmia ) can mitigate the course and reduce the need for emergency measures (1). These results have not yet been confirmed by larger studies, but have already received an inadequate response, including in the lay press. Should budesonide actually prove effective, this simple treatment would be seen as an advance in COVID-19. Due to many unanswered questions, we currently advise against an \u201coff-label\u201d application.<\/strong> … Artikel abonnieren<\/a> <\/p>\n\n\n

All articles for the keyword: <\/span><\/span>COVID-19,<\/h2>\n

Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions  2021, 55<\/b> , 37<\/a><\/p>\n

Thrombotic complications and thrombocytopenia after vaccination with Vaxzevria (formerly ChAdOx1 nCoV-19 vaccine)  2021, 55<\/b> , 36DB01<\/a><\/p>\n

Immunity to SARS-CoV-2 after infection  2021, 55<\/b> , 31<\/a><\/p>\n

The fourth vaccine against SARS-CoV-2 approved in the EU: Ad26.COV2.S  2021, 55<\/b> , 29<\/a><\/p>\n

Challenges for global access to vaccines against SARS-CoV-2  2021, 55<\/b> , 28DB01<\/a><\/p>\n

Update ChAdOx1 nCoV-19 vaccine  2021, 55<\/b> , 24<\/a><\/p>\n

Letter to the Editor: Ivermectin To Treat COVID-19?  2021, 55<\/b> , 19<\/a><\/p>\n

COVID-19 therapy: Current information on the importance of anticoagulation  2021, 55<\/b> , 16<\/a><\/p>\n

The first approved adenoviral vector vaccine against SARS-CoV-2: ChAdOx1 nCoV-19 (AZD1222)  2021, 55<\/b> , 13<\/a><\/p>\n

For medical information about vaccinations against COVID-19: legal aspects  2021, 55<\/b> , 12DB01<\/a><\/p>\n

The antidepressant fluvoxamine against COVID-19?  2021, 55<\/b> , 08b<\/a><\/p>\n

The neutralizing monoclonal antibody LY-CoV555 for the treatment of patients with COVID-19  2021, 55<\/b> , 08a<\/a><\/p>\n

The first two approved mRNA vaccines against COVID-19  2021, 55<\/b> , 01<\/a><\/p>\n

Update on the vaccines against SARS-CoV-2  2020, 54<\/b> , 99b<\/a><\/p>\n

Remdesivir: WHO SOLIDARITY study shows no convincing clinical benefit in COVID-19  2020, 54<\/b> , 95<\/a><\/p>\n

For the development of genetic vaccines against SARS-CoV-2 – technological approaches and clinical risks as a result of shortened test phases  2020, 54<\/b> , 85<\/a><\/p>\n

Remdesivir: Guideline for clinical use in patients with COVID-19 and new study results in moderately ill patients  2020, 54<\/b> , 80<\/a><\/p>\n

Glucocorticosteroids Reduce Mortality in Patients With Severe COVID-19 Course – A Prospective Meta-Analysis  2020, 54<\/b> , 79<\/a><\/p>\n

Humanitarian and utilitarian options for action by the state in view of the SARS-CoV-2 pandemic in Germany and considerations on better strategies for upcoming pandemics  2020, 54<\/b> , 76DB01<\/a><\/p>\n

Drug Treatments for COVID-19: Systematic Review and Network Meta-Analysis  2020, 54<\/b> , 72<\/a><\/p>\n

A considerable number of potentially protective T cells are found in people without SARS-CoV-2 infection  2020, 54<\/b> , 63<\/a><\/p>\n

First phase II studies with vaccines against COVID-19  2020, 54<\/b> , 62<\/a><\/p>\n

New European Medical  Device Regulation postponed by one year due to the SARS-CoV-2 pandemic 2020, 54<\/b> , 60DB01<\/a><\/p>\n

Remdesivir the first drug approved by the European Commission for the treatment of patients with COVID-19: more than a beacon of hope?  2020, 54<\/b> , 56<\/a><\/p>\n

Autopsy findings in COVID-19 patients with therapeutic consequences  2020, 54<\/b> , 52DB01<\/a><\/p>\n

Severe course of COVID-19: effectiveness of convalescent plasma  2020, 54<\/b> , 50<\/a><\/p>\n

COVID-19: The search for effective and safe drugs for drug therapy continues  2020, 54<\/b> , 48<\/a><\/p>\n

Epidemiology of SARS-CoV-2 infection on the „Diamond Princess“  2020, 54<\/b> , 44DB01<\/a><\/p>\n

SARS-CoV-2 antibody tests: careful interpretation of the results, no rapid tests!  2020, 54<\/b> , 41<\/a><\/p>\n

COVID-19: No evidence of an unfavorable course among ACE inhibitors and angiotensin-2 receptor blockers  2020, 54<\/b> , 40<\/a><\/p>\n

COVID-19: Scientific standards in clinical studies on pharmaceuticals must not be sacrificed to time pressure!  2020, 54<\/b> , 37<\/a><\/p>\n

Current aspects of the SARS-CoV-2 pandemic in Germany and Austria  2020, 54<\/b> , 30<\/a><\/p>\n

COVID-19: higher risk of infection and disease due to ACE inhibitors, AT-II receptor blockers and ibuprofen?  2020, 54<\/b> , 29<\/a><\/p>\n

Drug therapy for COVID-19: What do we know about the currently recommended but not yet approved drugs?  2020, 54<\/b> , 25<\/a><\/p>\n

A new coronavirus from China. Rational measures are required – no need to panic  2020, 54<\/b> , 09<\/a><\/p>\n

DER ARZNEIMITTELBRIEF<\/strong> erscheint als unabh\u00e4ngige Zeitschrift ohne Werbeanzeigen der Pharmaindustrie. Er wird ausschlie\u00dflich durch seine Leserinnen und Leser, d. h. durch die Abonnenten, finanziert. Wir bitten Sie deshalb um Verst\u00e4ndnis, dass wir aktuelle Artikel nur auszugsweise ver\u00f6ffentlichen k\u00f6nnen.<\/p>\n

Verl\u00e4ssliche Daten zu Arzneimitteln<\/strong>DER ARZNEIMITTELBRIEF<\/strong> informiert seit 1967 \u00c4rzte, Medizinstudenten, Apotheker und Angeh\u00f6rige anderer Heilberufe \u00fcber Nutzen und Risiken von Arzneimitteln.<\/p>\n

\n
\n
\n
\n

DER ARZNEIMITTELBRIEF<\/strong> erscheint als unabh\u00e4ngige Zeitschrift ohne Werbeanzeigen der Pharmaindustrie. Er wird ausschlie\u00dflich durch seine Leserinnen und Leser, d. h. durch die Abonnenten, finanziert. Wir bitten Sie deshalb um Verst\u00e4ndnis, dass wir aktuelle Artikel nur auszugsweise ver\u00f6ffentlichen k\u00f6nnen.<\/p>\n

\"2_Studi_Banner_AMB_NEU\"<\/a> \"DER<\/a> \"You<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

<\/p>","protected":false},"excerpt":{"rendered":"

AMB 2021, 55 , 37   Summary: A very small, controlled, randomized and open-label phase II study in 146 participants has shown that inhalation treatment with budesonide powder for a few days in patients with mild COVID-19 symptoms (cough, fever and \/ or anosmia ) can mitigate the course and reduce the need for emergency measures (1). These results […]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[],"class_list":["post-5397","post","type-post","status-publish","format-standard","hentry","category-allgemein"],"yoast_head":"\nBudesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"AMB 2021, 55 , 37   Summary: A very small, controlled, randomized and open-label phase II study in 146 participants has shown that inhalation treatment with budesonide powder for a few days in patients with mild COVID-19 symptoms (cough, fever and \/ or anosmia ) can mitigate the course and reduce the need for emergency measures (1). These results […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-22T11:49:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-22T11:50:24+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions\",\"datePublished\":\"2021-05-22T11:49:30+00:00\",\"dateModified\":\"2021-05-22T11:50:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/\"},\"wordCount\":799,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2_Studi_Banner_AMB_NEU.jpg\",\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/\",\"name\":\"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2_Studi_Banner_AMB_NEU.jpg\",\"datePublished\":\"2021-05-22T11:49:30+00:00\",\"dateModified\":\"2021-05-22T11:50:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2_Studi_Banner_AMB_NEU.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/2_Studi_Banner_AMB_NEU.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/","og_locale":"de_DE","og_type":"article","og_title":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief","og_description":"AMB 2021, 55 , 37   Summary: A very small, controlled, randomized and open-label phase II study in 146 participants has shown that inhalation treatment with budesonide powder for a few days in patients with mild COVID-19 symptoms (cough, fever and \/ or anosmia ) can mitigate the course and reduce the need for emergency measures (1). These results […]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2021-05-22T11:49:30+00:00","article_modified_time":"2021-05-22T11:50:24+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions","datePublished":"2021-05-22T11:49:30+00:00","dateModified":"2021-05-22T11:50:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/"},"wordCount":799,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg","inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/","name":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg","datePublished":"2021-05-22T11:49:30+00:00","dateModified":"2021-05-22T11:50:24+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/2_Studi_Banner_AMB_NEU.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/budesonide-inhalation-in-a-mild-course-of-covid-19-currently-too-many-unanswered-questions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Budesonide inhalation in a mild course of COVID-19: currently too many unanswered questions"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/5397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/comments?post=5397"}],"version-history":[{"count":2,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/5397\/revisions"}],"predecessor-version":[{"id":5399,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/posts\/5397\/revisions\/5399"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/media?parent=5397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/categories?post=5397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-json\/wp\/v2\/tags?post=5397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}